Author

Dajun Yang

Observed name: Yang, Dajun

Institutions: Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Ascentage Pharma Group Inc. (United States)

Observed institutions: Sun Yat-sen University, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Ascentage Pharma Group Inc. (United States)

OpenAlex ID: A5148698078

POSTER: ALL-589: Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive B-Cell Precursor Acute Lymphoblastic Leukemia

2026 · Elias Jabbour, Maria R. Baer, et al. · Clinical Lymphoma Myeloma & Leukemia

POSTER: AML-519: Target Dependence and Trial Design Drive Variable Outcomes With BH3 Mimetics in Hematologic Malignancies

2026 · Boyd Mudenda, Dajun Yang, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-519: Target Dependence and Trial Design Drive Variable Outcomes With BH3 Mimetics in Hematologic Malignancies

2026 · Boyd Mudenda, Dajun Yang, et al. · Clinical Lymphoma Myeloma & Leukemia

AML-599: BH3 Mimetics as Models for Precision Apoptosis Targeting: Functional Dependence, Adaptive Survival Networks, and Trial Design in Hematologic Malignancies

2026 · Boyd Mudenda, Dajun Yang, et al. · Clinical Lymphoma Myeloma & Leukemia

ALL-589: Olverembatinib Combined With Blinatumomab in Patients With Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome–Positive B-Cell Precursor Acute Lymphoblastic Leukemia

2026 · Elias Jabbour, Maria R. Baer, et al. · Clinical Lymphoma Myeloma & Leukemia

A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.

2026 · Elias Jabbour, Hagop M. Kantarjian, et al. · Journal of Clinical Oncology

A global multicenter, open-label, randomized, phase 3 registrational study of lisaftoclax (APG-2575) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): GLORA trial in progress.

2026 · Matthew Steven Davids, Sikander Ailawadhi, et al. · Journal of Clinical Oncology

Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph + BCP-ALL).

2026 · Elias Jabbour, Maria R. Baer, et al. · Journal of Clinical Oncology

Alrizomadlin (APG-115) alone or in combination with lisaftoclax (APG-2575) for the treatment of pediatric patients with relapsed/metastatic rhabdomyosarcoma (RMS) or other soft-tissue sarcomas (STSs).

2026 · Yizhuo Zhang, YI Zhang, et al. · Journal of Clinical Oncology

Updated clinical and translational results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)–deficient tumors.

2026 · Haibo Qiu, Zhiwei Zhou, et al. · Journal of Clinical Oncology

Abstract 4583: Multitarget kinase inhibitor olverembatinib (HQP1351) is efficacious and synergizes with chemotherapy in preclinical models of endometrial carcinoma (EC)

2026 · Yan Xiong, Zhiyan Liang, et al. · Cancer Research

Works count: 15

Citation count:

H-index:

I10-index: